Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1...

Area of Science:

• Genomics
• Oncology
• Immunotherapy

Background:

• Human genome stability relies on DNA polymerases.
• Defects in high-fidelity DNA polymerases, like DNA polymerase epsilon (Pol ε), are linked to genetic instability and cancer.
• Mutations in Pol ε are increasingly found in human cancers, but their clinical impact is unclear.

Observation:

• A young patient with aggressive stage IV colon cancer progressed rapidly on chemotherapy.
• The patient experienced a complete and durable response (>48 months) to single-agent checkpoint inhibitor immunotherapy.
• Genetic analysis revealed a POLE P286R mutation and high tumor mutational burden (126 mutations/Mb), despite negative PD-L1 staining.

Findings:

• The POLE mutation and high tumor mutational burden were associated with immunotherapy response.
• This case demonstrates a significant clinical benefit from immunotherapy in a patient with POLE-mutated colon cancer.
• The response occurred despite negative PD-L1 expression, suggesting alternative biomarkers for immunotherapy efficacy.

Implications:

• Genetic profiling, including POLE mutation status, is crucial for guiding cancer treatment decisions.
• Understanding the interplay between genetic instability (driven by POLE mutations) and immunotherapy response is vital.
• This case underscores the potential of immunotherapy for specific cancer subtypes characterized by DNA repair defects.